Objective. The aim of this study was to determine whether the activity of t
opoisomerase I (topo I), the target of the anti-neoplastic drug camptotheci
n (CPT), is elevated in cervical cancer and whether CPT can radiosensitize
cervical tumors.
Methods. The topo I activity of 11 normal cenix and 30 cervical carcinoma t
umors was assayed by measuring the relaxation of supercoiled DNA, Subconflu
ent or postconfluent CaSki human cervical carcinoma cells were exposed to C
PT (1-5000 ng/ml) and immediately X-irradiated (0-800 cGy), Cell survival w
as determined by clonogenic assay.
Results. Mean topo I activity in cervical cancer (3.0 +/- 0.06 h(-1)) was s
ignificantly greater than in normal cenix tissue (0.29 +/- 0.06 h(-1)). Sta
ge 3 and 4 cervical carcinoma specimens displayed a trend of greater topo I
activity (5.88 +/- 3.7 h(-1)) than stage 1 and 2 tumors (2.57 +/- 0.47 h(-
1)). No correlation between topo I protein levels and catalytic activity wa
s found. Combined treatment of subconfluent CaSki cells with CPT and ionizi
ng radiation resulted in additive killing of cells. Combined treatment of p
ostconfluent CaSki cells with low doses of radiation (200 and 400 cGy) and
1 or 10 ng/ml CPT for 2 or 48 h produced significant cytotoxicity compared
to CPT or radiation alone, which were ineffective at these doses,
Conclusions. Topo I activity is elevated in cervical cancer compared to nor
mal cervix, The radiosensitivity of noncycling cells within cervical tumors
may be increased by simultaneous treatment with low doses of CPT or other
topo I inhibitors. (C) 2000 Academic Press.